174 related articles for article (PubMed ID: 31037726)
1. Modulation of Myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors.
Tian M; Tian D; Qiao X; Li J; Zhang L
J Cell Physiol; 2019 Nov; 234(11):21126-21134. PubMed ID: 31037726
[TBL] [Abstract][Full Text] [Related]
2. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis.
Zhang XY; Zhu BC; He M; Dong SS
J Ovarian Res; 2024 May; 17(1):102. PubMed ID: 38745302
[TBL] [Abstract][Full Text] [Related]
3. Regulation of MYB mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis.
Zhang XY; Li YF; Ma H; Gao YH
Sci Rep; 2020 Apr; 10(1):6893. PubMed ID: 32327705
[TBL] [Abstract][Full Text] [Related]
4. Novel role of lncRNA CHRF in cisplatin resistance of ovarian cancer is mediated by miR-10b induced EMT and STAT3 signaling.
Tan WX; Sun G; Shangguan MY; Gui Z; Bao Y; Li YF; Jia ZH
Sci Rep; 2020 Sep; 10(1):14768. PubMed ID: 32901049
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate delivers hydrogen peroxide to induce death of ovarian cancer cells and enhances their cisplatin susceptibility.
Chan MM; Soprano KJ; Weinstein K; Fong D
J Cell Physiol; 2006 May; 207(2):389-96. PubMed ID: 16402374
[TBL] [Abstract][Full Text] [Related]
6. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
7. ID1 confers cancer cell chemoresistance through STAT3/ATF6-mediated induction of autophagy.
Meng J; Liu K; Shao Y; Feng X; Ji Z; Chang B; Wang Y; Xu L; Yang G
Cell Death Dis; 2020 Feb; 11(2):137. PubMed ID: 32080166
[TBL] [Abstract][Full Text] [Related]
8. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
[TBL] [Abstract][Full Text] [Related]
9. Sulforaphane regulates apoptosis- and proliferation‑related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer.
Kan SF; Wang J; Sun GX
Int J Mol Med; 2018 Nov; 42(5):2447-2458. PubMed ID: 30226534
[TBL] [Abstract][Full Text] [Related]
10. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.
Chen H; Landen CN; Li Y; Alvarez RD; Tollefsbol TO
Exp Cell Res; 2013 Mar; 319(5):697-706. PubMed ID: 23333498
[TBL] [Abstract][Full Text] [Related]
11. Epigallocatechin gallate sensitizes cisplatin-resistant oral cancer CAR cell apoptosis and autophagy through stimulating AKT/STAT3 pathway and suppressing multidrug resistance 1 signaling.
Yuan CH; Horng CT; Lee CF; Chiang NN; Tsai FJ; Lu CC; Chiang JH; Hsu YM; Yang JS; Chen FA
Environ Toxicol; 2017 Mar; 32(3):845-855. PubMed ID: 27200496
[TBL] [Abstract][Full Text] [Related]
12. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
13. Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling.
Chung SS; Vadgama JV
Anticancer Res; 2015 Jan; 35(1):39-46. PubMed ID: 25550533
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Eag1 Expression by RNA Interference Increases Chemosensitivity to Cisplatin in Ovarian Cancer Cells.
Hui C; Lan Z; Yue-li L; Li-lin H; Li-lin H
Reprod Sci; 2015 Dec; 22(12):1618-26. PubMed ID: 26079730
[TBL] [Abstract][Full Text] [Related]
16. DMBT1 suppresses cell proliferation, migration and invasion in ovarian cancer and enhances sensitivity to cisplatin through galectin-3/PI3k/Akt pathway.
Ma N; Zhao Y
Cell Biochem Funct; 2020 Aug; 38(6):801-809. PubMed ID: 32424818
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
18. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
19. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitor of c-Met (PHA665752) suppresses the growth of ovarian cancer cells and reverses cisplatin resistance.
Li E; Hu Z; Sun Y; Zhou Q; Yang B; Zhang Z; Cao W
Tumour Biol; 2016 Jun; 37(6):7843-52. PubMed ID: 26695152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
